Status:
COMPLETED
Efficacy and Safety ofCACXL in the Treatment of Keratoconus With Thin Corneas
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Progressive Keratoconus
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
The aim of this study is to detect the safety and effectiveness of contact lens assisted corneal cross linking in managing progressive keratoconus with thin corneas CACXL was done for 40 eyes of 30 of...
Detailed Description
Corneal collagen cross linking showed effective results in stabilizing progressive keratoconic corneas. It is the only treatment that halts progression of keratoconus, It was first described in 1998 b...
Eligibility Criteria
Inclusion
- Age from 18 to 35years old Mild , moderate and severe keratoconic patients with a corneal thickness from 360-400 µm at the thinnest location .
Exclusion
- • Previous corneal surgeries such as rings or crosslinking.
- Patients with stromal corneal scar.
- Other ocular pathology such as glaucoma or iridocyclitis.
- Patient with systemic diseases that likely affects wound healing such as insulin dependent diabetes mellitus.
- Patients with collagen vascular diseases, autoimmune or immune deficiency diseases.
- Pregnant or nursing women.
- Patients taking the following medications ; isotretinoin, amiodarone, sumatriptan.
- Other corneal pathology rather than keratoconus
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04504578
Start Date
January 1 2018
End Date
February 1 2019
Last Update
August 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kasrelaini Hospital
Cairo, Egypt, 12654